Actively Recruiting
Safety and Effectiveness Study of Autologous Tumor Infiltrating Lymphocytes GC101 in Adults with Advanced Non-Small Cell Lung Cancer
Led by Shanghai Juncell Therapeutics · Updated on 2026-08-05
20
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of autologous tumor infiltrating lymphocytes GC101 TIL in adults with advanced non-small cell lung cancer NSCLC who have not responded to prior treatments. This Phase Ib clinical trial aims to assess the safety and effectiveness of GC101 TIL infusion combined with low-dose PD-1 antibody therapy. The study focuses on patients with unresectable, recurrent, or metastatic NSCLC who have specific characteristics including measurable lesions and adequate organ function. Participants undergo a surgical procedure to obtain tumor samples, which are then cultured to generate the GC101 TIL cells. After a lymphodepletion process, patients receive an infusion of these cells followed by low-dose PD-1 antibody treatment. The study expects to enroll 20 participants and will be conducted over approximately 36 months, with treatment and follow-up phases included. During the trial, participants will be monitored closely through laboratory tests, physical exams, and imaging to evaluate adverse events up to 28 days and response rates at 18 weeks and beyond. Safety and effectiveness will also be assessed over a maximum of 36 months. Participants need to comply with scheduled visits, provide informed consent, and agree to contraception requirements if applicable. The study is sponsored by Shanghai Juncell Therapeutics and aims to gather detailed information on treatment outcomes and patient health over time.
CONDITIONS
Brief Title
A Phase Ib Study of GC101 in NSCLC
Research Team
S
Shun Lu, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here